drugset / Trial / NCT04460443

Sofosbuvir in Treatment of COVID 19

NCT04460443

Phase 2/3 Unknown 60 enrolled Tanta University
RandomizedParallel-groupOpen-labelTreatment

Summary

Sofosbuvir containing treatment in treatment of COVID 19 Egyptian patients

Timeline

Start
2020-08-01
Primary completion
2021-08-01
Completion
2021-08-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Daclatasvir Small molecule
Subject Sofosbuvir Small molecule
Subject ledipsavir Unknown

Indications